%0 Journal Article
%T Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
%A Aristotelis Bamias
%A Alexandra Karadimou
%A Sofia Lampaki
%A George Lainakis
%A Lia Malettou
%A Eleni Timotheadou
%A Kostas Papazisis
%A Charalambos Andreadis
%A Loukas Kontovinis
%A Ioannis Anastasiou
%A Kostas Stravodimos
%A Ioannis Xanthakis
%A Andreas Skolarikos
%A Christos Christodoulou
%A Kostas Syrigos
%A Christos Papandreou
%A Evangelia Razi
%A Urania Dafni
%A George Fountzilas
%A Meletios A Dimopoulos
%J BMC Cancer
%D 2010
%I BioMed Central
%R 10.1186/1471-2407-10-45
%X This is a retrospective analysis of patients treated in six Greek Oncology Units of HECOG. Inclusion criteria were: advanced renal cell carcinoma not amenable to surgery and treatment with Sunitinib. Previous cytokine therapy but no targeted agents were allowed. Overall survival (OS) was the major end point. Significance of prognostic factors was evaluated with multivariate cox regression analysis. A model was developed to stratify patients according to risk.One hundred and nine patients were included. Median follow up has been 15.8 months and median OS 17.1 months (95% CI: 13.7-20.6). Time from diagnosis to the start of Sunitinib (<= 12 months vs. >12 months, p = 0.001), number of metastatic sites (1 vs. >1, p = 0.003) and performance status (PS) (<= 1 vs >1, p = 0.001) were independently associated with OS. Stratification in two risk groups ("low" risk: 0 or 1 risk factors; "high" risk: 2 or 3 risk factors) resulted in distinctly different OS (median not reached [NR] vs. 10.8 [95% confidence interval (CI): 8.3-13.3], p < 0.001). The application of the MSKCC risk criteria resulted in stratification into 3 groups (low and intermediate and poor risk) with distinctly different prognosis underlying its validity. Nevertheless, MSKCC model did not show an improved prognostic performance over the model developed by this analysis.Studies on risk stratification of patients with advanced RCC treated with targeted therapies are warranted. Our results suggest that a simpler than the MSKCC model can be developed. Such models should be further validated.Renal cancer is the third most frequent malignancy of the urinary tract and accounts for 3% of all adult malignancies [1]. Most patients (70-80%) presenting with localized disease can be cured with surgery. On the contrary, advanced disease or relapses after radical nephrectomy is usually incurable. In total, nearly 50% of patients with renal cell carcinoma will present with or develop metastatic disease [1,2]. Prognosis in patie
%U http://www.biomedcentral.com/1471-2407/10/45